Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice

FEMS Immunology and Medical Microbiology

Volumn 41, Issue 3, 2004, Pages 205-210

  Fukasawa, Lucila O ^a   Dias, Waldely O ^a   Schenkman, Rocilda P F ^a   Raw, I ^a   Tanizaki, Martha M ^a  

^a INSTITUTO BUTANTAN   (Brazil)

Author keywords

Adjuvant; Anti meningococcal vaccine; Capsular polysaccharide; MF59; Newborn mice; Outer membrane vesicle

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; ANTIBODY; IMMUNOGLOBULIN G; MENINGOCOCCUS VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; OUTER MEMBRANE PROTEIN; PHOSPHORYL LIPID A; POLYSACCHARIDE; TITERMAX; UNCLASSIFIED DRUG;

ARTICLE; BLOOD GROUP TYPING; BRAZIL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNE RESPONSE; MEMBRANE VESICLE; MOUSE; NEISSERIA MENINGITIDIS; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SEROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANIMALS, NEWBORN; ANTIBODY AFFINITY; BACTERIAL OUTER MEMBRANE PROTEINS; BLOOD BACTERICIDAL ACTIVITY; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULIN G; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MICE; NEISSERIA MENINGITIDIS, SEROGROUP B; NEISSERIA MENINGITIDIS, SEROGROUP C; POLYSACCHARIDES, BACTERIAL; POLYSORBATES; SQUALENE; VACCINES, CONJUGATE;

EID: 2942610585     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.femsim.2004.03.005     Document Type: Article

References (35)

1. Collins C.L., Pollard A.J. Meningococcal vaccines. Curr. Opin. Invest. Drugs. 3:2002;975-979
2. Borrow R., Goldblatt D., Andrews N., Southern J., Ashton L., Deane S., Morris R., Cartwright K., Miller E. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J. Infect. Dis. 186:2002;1353-1357
3. Bose A., Coen P., Tully J., Viner R., Booy R. Effectiveness of meningococcal C conjugate vaccine in teenagers in England. Lancet. 361:2003;675-675
4. Joseph H., Ryall J.H., Bybel M., Papa T., MacLennan J., Buttery J., Borrow R. Immunogenicity and immunological priming of the serogroup a portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children. J. Infect. Dis. 187:2003;1142-1146
5. Finne J., Bitter-Sueneman D., Goridis C., Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysalic acid units of glicoproteins in neural and extraneural tissues. J. Immunol. 138:1987;402-407
6. Zollinger W.D. New and improved vaccines against meningococcal disease. Levine M.M., Woodrow G.C., Kaper J.B., Cobon G.S. New Generation Vaccines. 1997;469-488 Marcel Dekker, New York
7. Pollard A.J., Levin M. Vaccines for prevention of meningococcal disease. Pediatr. Infect. Dis. J. 19:2000;333-345
8. Milagres L.G., Ramos S.R., Sacchi C.T. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect. Immun. 62:1994;4419-4424
9. Noronha C.P., Struchiner C.J., Halloran M.E. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case control study. Int. J. Epidemiol. 24:1995;1050-1057
10. Lonsworth E., Borrow R., Goldblatt D., Balmer P., Dawson H., Andrews N., Miller E., Cartwright K. Avidity maturation following vaccination with a meningococcal recombinant haxavalent PorA OMV vaccine in UK infants. Vaccine. 20:2002;2592-2596
11. Pollard A.J., Galassini R., Roupe van der Voort E.M., Hibberd M., Booy R., Langford P., Nadel S., Ison C., Kroll J.S., Poolman J., Levin M. Humoral immune responses to Neisseria meningitids in children. Infect. Immun. 67:1999;224-2251
12. Pollard A.J., Levin M. Production of low avidity antibody by infants after infection with serogroup B meningococci. Lancet. 356:2000;2065-2066
13. Fukasawa L.O., Gorla M.C.O., Schenkman R.P.F., Garcia L.R., Carneiro S.M., Raw I., Tanizaki M.M. Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate. Vaccine. 17:1999;2951-2958
14. Gómes J.A., Hernandez E., Criado M.T., Ferreirós C.M. Effect of adjuvants in the isotypes and bactericidal activity of antibodies against the transferrin-binding proteins of Neisseria meningitidis. Vaccine. 16:1998;1633-1639
15. Steeghs L., Kuipers B., Hamstra H.J., Kersten G., van Alphen L., van der Ley P. Immunogenicity of outer membrane proteins in a lipopolysaccharide- deficient mutant of Neisseria meningitidis: influence of adjuvants on the immune response. Infect. Immun. 67:1999;4988-4993
16. Frasch C.E., Zahradik L.D., Wang L.Y., Mocca L.F., Tsai C.M. Antibody response of adults to an aluminum hydroxide-adsorbed Neisseria meningitidis serotype 2b protein group B polysaccharide vaccine. J. Infect. Dis. 158:1988;710-718
17. Granoff D.M., Maslanka S.E., Carlone G.M., Plikaytis B.D., Santos G.F., Mokatrin A., Raff H.V. A modified enzyme-linked immunosorbent assay for measurement of antibody response to meningococcal C polysaccharide that correlate with bactericidal responses. Clin. Diagn. Lab. Immunol. 5:1998;479-485
18. Vermont C.L., van Dijken C.J., van Limpt C.J.P., de Groot R., van Alphen L., van den Dobbelsteen G.P.J.M. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outermembrane vesicle vaccine. Infect. Immun. 70:2002;584-590
19. Sierra G.V.G., Campa H.C., Varcarel N.M. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14:1991;195-210
20. Bosleggo J., Garcia J., Cruz C. Efficacy, safety and immunogenicity of a meningococcal group B (15:P1.3) outer membrane vesicle vaccine in Iquique, Chile. Vaccine. 13:1995;821-829
21. Tappero J.W., Lagos R., Ballesteros A.M., Plikaytis B., Williamas D., Dykes J., Gheeling L.L., Carlone G.M., Hoiby E.A., Holst J., Nekleby H., Rosenqvist E., Sierra G., Campa C., Sotolongo F., Vega J., Garcia J., Herrera P., Poolman J.T., Perkins B.A. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA. 281:1999;1541-1543
22. Kovarik J., Siegrist C.A. Optimization of vaccine responses in early life: the role of delivery systems and immunomodulators. Immunol. Cell Biol. 76:1998;222-236
23. Halperin S.A., Mc Donald J., Samson L., Danzig L., Santos G., Smith B., Mc Donald N. Simultaneous administration of meningococcal C conjugate vaccine and diphteria-tetanus-acellular petussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study. Clin. Invest. Med. 25:2002;243-251
24. 197 conjugate vaccine. Infect. Immun. 65:1997;1710-1715
25. Einhorn M.S., Weinberg G.A., Anderson E.L., Granoff P.D., Granoff D.M. Immunogenicity in infants of Haemophilus influenzae type b polysaccharide in a conjugate vaccine with Neisseria meningitids outer-membrane protein. Lancet. 2:1986;299-302
26. Wetzler L.M. Immunopotenciating ability of neisserial major outer membrane proteins. Ann. NY Acad. Sci. 730:1994;367-370
27. Wetzler L.M., Ho Y., Reiser H. Nesserial porins induce B lymphocytes to express coestimulatory B7-2 molecules and to proliferate. J. Exp. Med. 183:1996;1151-1159
28. Liu M.A., Friedman A., Oliff A.I., Tai J., Martinez D., Deck R.R., Shieh J.T., Jenkins T.D., Donnelly J.J., Hawe L.A. A vaccine carrier derived from Neisseria meningitidis with mitogenic activity for lymphocytes. Proc. Natl. Acad. Sci. USA. 89:1992;4633-4637
29. Pérez-Melgosa M., Ochs H.D., Linsley P.S., Laman J.D., van Meurs M., Flavell R.A., Erst R.K., Miller S.I., Wilson C.B. Carrier-mediated enhancement of cognate T cell help: the basis of enhanced immunogenicity of meningococcal outer membrane protein polysaccharide conjugate vaccine. Eur. J. Immunol. 31:2001;2373-2381
30. Sacchi C.T., Lemos A.P., Popovic T., De Morais J.C., Whitney A.M., Melles C.E., Brondi L.M., Monteiro L.M., Paiva M.V., Solari C.A., Mayer L.W. Serosubtypes and Por A types of Neisseria meningitidis serogroup B isolated in Brazil during 1997-1998: overview and implications for vaccine development. J. Clin. Microbiol. 39:2001;2897-2903
31. Fukasawa L.O., Gorla M.C.O., Lemos A.P.S., Schenkman R.P.F., Brandileone M.C.C., Fox J.W., Raw I., Frasch C.E., Tanizaki M.M. Immune response to native NadA from Neisseria meningitidis and its expression in clinical isolates in Brazil. J. Med. Microbiol. 52:2003;121-125
32. Asa P.B., Wilson R.B., Garry R.F. Antibodies to squalene in recipients of anthrax vaccine. Exp. Mol. Path. 73:2002;19-27
33. Gasparini R., Pozzi T., Montomoli E., Fragapane E., Senatore F., Minutello M., Podda A. Increased immunogenicity of the MF-59 adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur. J. Epidemiol. 184:2001;1331-1335
34. Ballou W.R., Reed J.L., Noble W., Young N.S., Koening S. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C. J. Infect. Dis. 187:2003;675-678
35. Ott G., Radhakrishnan R., Fanf J.H., Hora M. The adjuvant MF59: a 10 year perspective. O'Hagan D.T. Vaccine Adjuvants. Preparation Methods and Research Protocols. 2000;211-228 Humana Press Inc, New Jersey